Skip to main content
. 2019 Nov 22;59(3):311–326. doi: 10.1007/s40262-019-00842-5

Table 7.

PASI and sPGA0/1 responses by ADA status at weeks 16 and 52 in subjects treated with risankizumab 150 mg SC at weeks 0 and 4, and every 12 weeks thereafter in global phase III studies

Efficacy response (NRI) Week 16 (placebo-controlled) [n = 1000] Week 52 (ustekinumab-controlled) [n = 598]
ADA-negative [n = 819] ADA-positive with ADA titer < 128 [n = 174] ADA-positive with ADA titer ≥128 [n = 7] ADA-negative [n = 456] ADA-positive with ADA titer < 128 [n = 136] ADA-positive with ADA titer ≥128 [N = 6]
PASI 75 735 (89.7) 155 (89.1) 5 (71.4) 414 (90.8) 130 (95.6) 4 (66.7)
PASI 90 610 (74.5) 131 (75.3) 2 (28.6) 377 (82.7) 106 (77.9) 3 (50.0)
PASI 100 372 (45.4) 76 (43.7) 1 (14.3) 270 (59.2) 75 (55.1) 1 (16.7)
sPGA 0/1 695 (84.9) 150 (86.2) 4 (57.1) 385 (84.4) 120 (88.2) 2 (33.3)

Data are expressed as n (%)

There were additional subjects who developed treatment-emergent ADA response with ADA titers ≥ 128 in phase III studies; however, these subjects did not receive the proposed clinical regimen of risankizumab (150 mg SC at weeks 0 and 4, and every 12 weeks thereafter), and hence were not included in this analysis

ADA antidrug antibody, NRI non-responder imputation, PASI Psoriasis Area and Severity Index, sPGA static Physicians Global Assessment, SC subcutaneous